Aim: Recurrent thrombotic events still occur despite dual antiplatelet therapy in patient's post percutaneous coronary intervention (PCI) could be attributed to high on-treatment platelet reactivity.
Methods: A 44-year-old male, who had staged PCI to left anterior descending (LAD) 2 weeks after an anterior MI, with a drug-coated stent was readmitted with new anterior STEMI 35 days later. Coronary angiogram revealed mid-stent thrombus in situ. He had further uncomplicated PCI. Platelet function testing and genotyping showed clopidogrel high on-treatment platelet reactivity and CYP2C19*3/*17 genotype. Ticagrelor was commenced.
Results & Conclusion: This case study is the first reported in Malaysia to document a patient with a CYP2C19*3/*17 genotype presenting with a stent thrombosis after an uncomplicated index PCI procedure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs-2018-0082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.
Indian Heart J
November 2023
Center of Excellence in Molecular Biology and Regenerative Medicine, Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru, India; Special Interest Group - Human Genomics and Rare Disorders, JSS Academy of Higher Education & Research, Mysuru, India. Electronic address:
Article Synopsis
- This study investigates the prevalence of CYP2C19 alleles, focusing on loss-of-function (LoF) alleles (CYP2C19∗2, CYP2C19∗3) and gain-of-function (GoF) alleles (CYP2C19∗17) in a population of 300 healthy adults.
- Researchers used allele-specific PCR to determine the frequencies of these alleles and the resulting metabolic phenotypes (ultra-rapid, extensive, intermediate, and poor metabolizers).
- Results showed a high frequency of poor metabolizers (12.67%) and recommended pre-treatment genotype testing to tailor drug dosages and reduce adverse effects.
Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China.
Genet Res (Camb)
November 2022
Department of Cardiology, Qinghai Provincial People's Hospital, Xining, Qinghai 810007, China.
Objective: Clopidogrel is widely used for preventing ischemic complications related to cardiovascular diseases. However, many patients experience clopidogrel resistance (CR). The polymorphisms of CYP2C19 have been implicated in CR, but CYP2C19 polymorphism considerably varies with both ethnic group and geographical location.
View Article and Find Full Text PDFCYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression.
Heliyon
May 2020
Department of Pharmacology, Laboratory of Biochemistry and Molecular Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Article Synopsis
- Escitalopram (ESC) is a medication used to treat depression and anxiety, predominantly metabolized by the enzyme CYP2C19, which varies among individuals due to genetic differences.
- A study involving 31 patients with major depressive disorder (MDD) found that different CYP2C19 genetic profiles affected how these patients responded to ESC, with ultrarapid metabolizers needing higher doses for treatment.
- The findings suggest that patients with the CYP2C19 ultrarapid metabolizer phenotype may require higher doses or combination therapy to achieve remission from MDD, highlighting the importance of genetic factors in antidepressant treatment.
Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients.
Mycoses
November 2020
Department of Pharmacy, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China.
Background: Effects of CYP2C19 polymorphism on voriconazole concentration (C ), dose-adjusted trough concentrations (C /dose) and voriconazole-to-voriconazole-N-oxide concentration ratio (C /C ) have not been fully investigated.
Objectives: To investigate correlations of CYP2C19 polymorphisms with plasma concentrations of voriconazole and the major metabolite voriconazole-N-oxide in elderly patients.
Methods: A prospective, multi-centre, non-intervention, open clinical study was conducted within Southwestern Chinese patients clinically diagnosed with invasive fungal infections, to investigate the associations of CYP2C19∗2 (681G > A), CYP2C19∗3 (636G > A) and CYP2C19∗17 (-806C > T) genetic polymorphisms with voriconazole C , C /dose and C /C .
Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events.
Chin Med J (Engl)
May 2019
Department of Neurology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, China.
Background: High on-treatment platelet reactivity (HTPR) has been suggested as a risk factor for patients with ischemic vascular disease. We explored a predictive model of platelet reactivity to clopidogrel and the relationship with clinical outcomes.
Methods: A total of 441 patients were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!